

FOR IMMEDIATE RELEASE

Sun Pharma leverages mobile technology to boost treatment compliance amongst asthma patients

- *Rolls-out India's first Asthma monitoring mobile App, RespiTrack, to connect doctor & patient*
- *Nearly 70% Asthma patients in India do not adhere to prescribed treatment regimen*

MUMBAI – MAY 9, 2016: As part of its focus to give boost to treatment compliance amongst Asthma patients by minimizing instances of non-adherence and drop-outs in Asthma treatment regime, Sun Pharma Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, Sun Pharmaceutical Industries Ltd and includes its subsidiaries or associate companies) is rolling out India's first unique & innovative mobile application that will connect Doctors and Asthma patients. This App has been specifically developed by Sun Pharma for enabling doctors to track treatment progress of their patients and increase compliance to medication for better management of asthma disease.

It is estimated that nearly 50% to 70% patients in India do not adhere to asthma treatment regimen recommended by a doctor. Up to 50% of such non-adherence is on account of the patient's forgetfulness to take medicines on time and due to inadequate understanding of the prescribed treatment regimen. Sun Pharma's RespiTrack aims to address these and other reasons leading to non-adherence thereby improving compliance to Asthma treatment through recurring medication reminders, pre-programmed alerts, Over-the-Air review by the doctor etc.

Commenting on its RespiTrack mobile Application, Mr. Abhay Gandhi, CEO – India Business, Sun Pharma said, *“Unlike other chronic illnesses where non-adherence to treatment regimen could have significant impact on the patient's health, Asthmatics tend to be low on the short-run adversity impact of non-adherence. However, in the long run, the implications of non-adherence to prescribed Asthma treatment can severely impede quality of life of these patients. By leveraging our digital technology capabilities, we believe RespiTrack can address this unmet need by reducing non-adherences incidences to treatment.”*

For an Asthma patient, RespiTrack allows complete monitoring of asthma attacks, symptoms and medications prescribed by the physician. It enables these patients to record time, place, duration & triggers of attacks along with medication details on the mobile App. The patient can easily send this data to the consulting physician through over-the-air mode on a weekly or monthly basis. RespiTrack also offers a review dashboard that gives a snapshot of all parameters to monitor over a period of time.

Through RespiTrack, a doctor can access his patient's details through a personalized tracker module which is directly synced with the patient's App. This module allows doctors to access patient's ailment

Sun Pharmaceutical Industries Ltd.
SUN HOUSE, CTS No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
CIN: L24230GJ1993PLC019050
www.sunpharma.com



history, attack patterns, symptoms, medication patterns and reports. A doctor can remotely view patient reports and also connect with them through an integrated messaging app.

As per WHO Report, India has an estimated 15-20 million asthmatic patients. Various studies estimate that nearly 40% of Asthma patients use inhalers and the rest prefer oral formulations.

Sun Pharma's RespiTrack is available on Google Play Store & Apple Store. A patient needs a Registration Number issued by his/her doctor to use this App.

About Sun Pharmaceutical Industries Ltd: (CIN - L24230GJ1993PLC019050)

Sun Pharma is world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun Pharma's global presence is supported by 49 manufacturing facilities spread across 6 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. The consolidated revenues for 12 months ending March 2015 are approximately US\$ 4.5 billion, of which US contributes US\$ 2.2 billion. In India, the company enjoys leadership across 12 different classes of doctors with 30 brands featuring amongst top 300 pharmaceutical brands in India. Its footprint across emerging markets covers over 100 markets and 6 markets in Western Europe. Its Global Consumer Healthcare business is ranked amongst Top 10 across 4 global markets. Its API business footprint is strengthened through 14 world class API manufacturing facilities across the globe. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising about 2,000 scientists and R&D investments of over 7% of annual revenues.

For more details please visit www.sunpharma.com.

Follow us on Twitter @SunPharma_Live

FOR FURTHER DETAILS PLEASE CONTACT SUN PHARMA CORPORATE COMMUNICATIONS

Frederick Castro | +91 9920665176 | frederick.castro@sunpharma.com

Gaurav Chugh | +91 9810471414 | gaurav.chugh@sunpharma.com

INVESTOR RELATIONS CONTACT

Nimish Desai | +91 9820330182 | nimish.desai@sunpharma.com